File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Current Status and Challenges of NRF2 as a Potential Therapeutic Target for Diabetic Cardiomyopathy

TitleCurrent Status and Challenges of NRF2 as a Potential Therapeutic Target for Diabetic Cardiomyopathy
Authors
KeywordsReactive oxygen species
Diabetes mellitus
Cancer
Issue Date2019
PublisherInternational Heart Journal Association. The Journal's web site is located at http://square.umin.ac.jp/ihj/EN/index.html
Citation
International Heart Journal, 2019, v. 60 n. 3, p. 512-520 How to Cite?
AbstractDiabetic cardiomyopathy is one of the main causes of heart failure and death in patients with diabetes mellitus. Reactive oxygen species produced excessively in diabetes mellitus cause necrosis, apoptosis, ferroptosis, inflammation, and fibrosis of the myocardium as well as impair the cardiac structure and function. It is increasingly clear that oxidative stress is a principal cause of diabetic cardiomyopathy. The transcription factor nuclear factor-erythroid 2 p45-related factor 2 (NRF2) activates the transcription of more than 200 genes in the human genome. Most of the proteins translated from these genes possess anti-oxidant, anti-inflammatory, anti-apoptotic, anti-ferroptotic, and anti-fibrotic actions. There is a growing body of evidence indicating that NRF2 and its target genes are crucial in preventing high glucose-induced oxidative damage in diabetic cardiomyopathy. Recently, many natural and synthetic activators of NRF2 are shown to possess promising therapeutic effects on diabetic cardiomyopathy in animal models of diabetic cardiomyopathy. Targeting NRF2 signaling by pharmacological entities is a potential approach to ameliorating diabetic cardiomyopathy. However, the persistent high expression of NRF2 in cancer tissues also protects the growth of cancer cells. This 'dark side' of NRF2 increases the challenges of using NRF2 activators to treat diabetic cardiomyopathy. In addition, some NRF2 activators were found to have off-target effects. In this review, we summarize the current status and challenges of NRF2 as a potential therapeutic target for diabetic cardiomyopathy.
DescriptionLink to Free access
Persistent Identifierhttp://hdl.handle.net/10722/293260
ISSN
2019 Impact Factor: 1.906
2015 SCImago Journal Rankings: 0.608

 

DC FieldValueLanguage
dc.contributor.authorg, ZD-
dc.contributor.authorl, Q-
dc.contributor.authorm, X-
dc.contributor.authorXia, Z-
dc.date.accessioned2020-11-23T08:14:09Z-
dc.date.available2020-11-23T08:14:09Z-
dc.date.issued2019-
dc.identifier.citationInternational Heart Journal, 2019, v. 60 n. 3, p. 512-520-
dc.identifier.issn1349-2365-
dc.identifier.urihttp://hdl.handle.net/10722/293260-
dc.descriptionLink to Free access-
dc.description.abstractDiabetic cardiomyopathy is one of the main causes of heart failure and death in patients with diabetes mellitus. Reactive oxygen species produced excessively in diabetes mellitus cause necrosis, apoptosis, ferroptosis, inflammation, and fibrosis of the myocardium as well as impair the cardiac structure and function. It is increasingly clear that oxidative stress is a principal cause of diabetic cardiomyopathy. The transcription factor nuclear factor-erythroid 2 p45-related factor 2 (NRF2) activates the transcription of more than 200 genes in the human genome. Most of the proteins translated from these genes possess anti-oxidant, anti-inflammatory, anti-apoptotic, anti-ferroptotic, and anti-fibrotic actions. There is a growing body of evidence indicating that NRF2 and its target genes are crucial in preventing high glucose-induced oxidative damage in diabetic cardiomyopathy. Recently, many natural and synthetic activators of NRF2 are shown to possess promising therapeutic effects on diabetic cardiomyopathy in animal models of diabetic cardiomyopathy. Targeting NRF2 signaling by pharmacological entities is a potential approach to ameliorating diabetic cardiomyopathy. However, the persistent high expression of NRF2 in cancer tissues also protects the growth of cancer cells. This 'dark side' of NRF2 increases the challenges of using NRF2 activators to treat diabetic cardiomyopathy. In addition, some NRF2 activators were found to have off-target effects. In this review, we summarize the current status and challenges of NRF2 as a potential therapeutic target for diabetic cardiomyopathy.-
dc.languageeng-
dc.publisherInternational Heart Journal Association. The Journal's web site is located at http://square.umin.ac.jp/ihj/EN/index.html-
dc.relation.ispartofInternational Heart Journal-
dc.subjectReactive oxygen species-
dc.subjectDiabetes mellitus-
dc.subjectCancer-
dc.titleCurrent Status and Challenges of NRF2 as a Potential Therapeutic Target for Diabetic Cardiomyopathy-
dc.typeArticle-
dc.identifier.emailXia, Z: zyxia@hkucc.hku.hk-
dc.identifier.authorityXia, Z=rp00532-
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1536/ihj.18-476-
dc.identifier.pmid30971629-
dc.identifier.scopuseid_2-s2.0-85067268858-
dc.identifier.hkuros319856-
dc.identifier.volume60-
dc.identifier.issue3-
dc.identifier.spage512-
dc.identifier.epage520-
dc.publisher.placeJapan-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats